Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC14402TriptolideCAS: 38748-32-2纯度: >99.50% / >99.00% / >98.00%
雷公藤甲素(Triptolide)是一种二萜三环氧化物,首次从药用植物雷公藤 (Tripterygium wilfordii) 中分离出来,具有免疫抑制,抗炎,抗增殖和抗肿瘤作用。
- GC14976Lenalidomide (CC-5013)CAS: 191732-72-6纯度: >99.50%
Lenalidomide (CC-5013)是thalidomide的4-氨基-谷氨酰类似物,具有更强的效力,且不具有thalidomide相关的镇静和神经病变等神经系统副作用。
- GC15371BardoxoloneCAS: 218600-44-3纯度: >98.00%
An anti-inflammatory compound that activates Nrf2/ARE signaling
- GA11219Tos-Arg-OMe·HClCAS: 1784-03-8纯度: >98.00%
Tos-Arg-OMe.HCl 是后期促进复合物/环体(APC/C 或 APC)的抑制剂,它与 APC/C 结合并阻止其被 Cdc20 和 Cdh1 激活,产生有丝分裂停滞。 Tos-Arg-OMe.HCl 不具有细胞渗透性。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC13803 | Triflurdine (Viroptic) | 70-00-8 | >99.50% | |
A thymidine analog that inhibits DNA synthesis | ||||
| GC14188 | Z-YVAD-FMK | 210344-97-1 | >98.00% | |
Z-YVAD-FMK是一种可穿透细胞的不可逆caspase-1和caspase-4 抑制剂。 | ||||
| GC14402 | Triptolide | 38748-32-2 | >99.50% / >99.00% / >98.00% | |
雷公藤甲素(Triptolide)是一种二萜三环氧化物,首次从药用植物雷公藤 (Tripterygium wilfordii) 中分离出来,具有免疫抑制,抗炎,抗增殖和抗肿瘤作用。 | ||||
| GC14787 | Curcumin | 458-37-7 | >98.00% | |
A yellow pigment with diverse biological activities | ||||
| GC14853 | TC ASK 10 | 1005775-56-3 | >99.00% | |
A inhibitor of ASK1 | ||||
| GC14976 | Lenalidomide (CC-5013) | 191732-72-6 | >99.50% | |
Lenalidomide (CC-5013)是thalidomide的4-氨基-谷氨酰类似物,具有更强的效力,且不具有thalidomide相关的镇静和神经病变等神经系统副作用。 | ||||
| GC15217 | Danusertib (PHA-739358) | 827318-97-8 | >98.50% | |
A pan-Aurora kinase and Abl inhibitor | ||||
| GC15307 | SU5416 | 204005-46-9,194413-58-6 | >98.00% | |
SU5416 是一种有效的小分子血管内皮生长因子受体 (VEGFR) 抑制剂。 | ||||
| GC15371 | Bardoxolone | 218600-44-3 | >98.00% | |
An anti-inflammatory compound that activates Nrf2/ARE signaling | ||||
| GC15718 | CID 2011756 | 638156-11-3 | - | |
An inhibitor of protein kinase D | ||||
| GC16051 | Nutlin-3 | 890090-75-2 | >99.00% / >98.00% | |
A racemic mixture of (?)-nutlin-3 and (+)-nutlin-3 | ||||
| GC16116 | Costunolide | 553-21-9 | >99.00% / >98.00% | |
A natural sesquiterpene lactone | ||||
| GC16391 | Amuvatinib (MP-470, HPK 56) | 850879-09-3 | >98.00% | |
A multi-targeted RTK inhibitor | ||||
| GC16762 | BMS-202 | 1675203-84-5 | >99.00% | |
BMS-202是一种非肽性PD-1/PD-L1复合物抑制剂,与PD-L1隔离PD-1/PD-L1二聚体形成(IC 50 =53.6nM),以结合阻断人PD-1/PD-L1相互作用,从而抑制免疫反应抑制,从而阻止癌细胞逃避抗肿瘤免疫反应。 | ||||
| GC16806 | R18 | 211364-78-2 | - | |
R18 是 14-3-3 的肽拮抗剂,KD 为 70-90 nM。 R18 有效阻断 14-3-3 与激酶 Raf-1(14-3-3 的生理配体)的结合,并有效消除 14-3-3 对磷酸酶诱导的 Raf-1 失活的保护作用。 | ||||
| GC17234 | ABT-737 | 852808-04-9 | >98.00% | |
ABT-737作为一种BH3模拟药物,是Bcl-2家族的抑制剂,可抑制Bcl2、Bcl-xL和Bcl-w的活性,IC 50 值<1nM。 | ||||
| GC17851 | D609 | 83373-60-8 | >98.00% | |
A competitive inhibitor of PC-specific PLC | ||||
| GC17960 | U 73343 | 142878-12-4 | >99.00% | |
U 73343是U 73122的非活性类似物。 | ||||
| GC19771 | STM2457 | 2499663-01-1 | >99.50% / ≥99.50% / >98.00% | |
An inhibitor of the METTL3/14 complex | ||||
| GN10531 | Dimethylfraxetin | 6035-49-0 | >99.50% | |
A coumarin with anti-inflammatory activity | ||||
| GA11219 | Tos-Arg-OMe·HCl | 1784-03-8 | >98.00% | |
Tos-Arg-OMe.HCl 是后期促进复合物/环体(APC/C 或 APC)的抑制剂,它与 APC/C 结合并阻止其被 Cdc20 和 Cdh1 激活,产生有丝分裂停滞。 Tos-Arg-OMe.HCl 不具有细胞渗透性。 | ||||
| GA20156 | (D-Ser(tBu)⁶,Azagly¹⁰)-LHRH (free base) | 65807-02-5 | - | |
| GA20494 | Ac-Asp-Glu-Val-Asp-pNA | 189684-50-2 | - | |
A colorimetric caspase substrate | ||||
| GA20897 | Boc-Arg(Boc)₂-OH | 97745-69-2 | - | |
An amino acid building block | ||||
